Disc Medicine Announces $90 Million Series B Financing To Advance Portfolio Of Clinical-Stage Therapies For Hematologic Diseases
Disc Medicine Announces $90 Million Series B Financing To Advance Portfolio Of Clinical-Stage Therapies For Hematologic Diseases
09/02/21, 10:04 AM
Location
cambridgeMoney raised
$90 million
Round Type
series b
Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, today announced a $90 million Series B financing from a leading syndicate of investors. The financing was led by OrbiMed with participation from new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management, Willett Advisors, and Alexandria Venture Investments. Existing investors also participated in the financing, including Atlas Venture, Novo Holdings and Access Biotechnology.
Company Info
Location
cambridge, maryland, united states
Additional Info
Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates based on fundamental pathways of red blood cell biology. Disc Medicine is committed to building a brighter future for patients who suffer from hematologic disease, ranging from severe orphan conditions to widely prevalent diseases. For more information, please visit www.discmedicine.com.
SOURCE Disc Medicine